Aldosterone induced galectin-3 secretion in vitro and in vivo: From cells to humans

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Lin, Yen Hung ^a   Chou, Chia Hung ^a   Wu, Xue Ming ^b   Chang, Yi Yao ^c   Hung, Chi Sheng ^a   Chen, Ying Hsien ^a   Tzeng, Yu Lin ^a   Wu, Vin Cent ^a   Ho, Yi Lwun ^a   Hsieh, Fon Jou ^a   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAO YUAN GENERAL HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; GALECTIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; MESSENGER RNA;

ADRENALECTOMY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FIBROBLAST; GALECTIN 3 GENE; GENE EXPRESSION REGULATION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY HYPERALDOSTERONISM; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; GENETICS; HEART MUSCLE; HYPERALDOSTERONISM; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TIME;

ADRENALECTOMY; ALDOSTERONE; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FIBROSIS; GALECTIN 3; GENE EXPRESSION REGULATION; HUMANS; HYPERALDOSTERONISM; MALE; MICE; MYOCARDIUM; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84907462313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095254     Document Type: Article

References (33)

1. Rossi GP (2010) Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep 12: 342-348.
2. Weber KT, Gerling IC, Kiani MF, Guntaka RV, Sun Y, et al. (2003) Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 4: 505-516. (Pubitemid 36869223)
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717. (Pubitemid 29407370)
4. Brilla CG, Weber KT (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26: 671-677.
5. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, et al. (2002) Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40: 23-27. (Pubitemid 34755974)
6. Kozakova M, Buralli S, Palombo C, Bernini G, Moretti A, et al. (2003) Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 41: 230-236. (Pubitemid 36204894)
7. Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, et al. (1996) Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension 27: 319-323. (Pubitemid 26082073)
8. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, et al. (2007) Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50: 911-918. (Pubitemid 350287534)
9. Lin YH, Lee HH, Liu KL, Lee JK, Shih SR, et al. (2011) Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery 150: 526-533.
10. Lin YH, Wu XM, Lee HH, Lee JK, Liu YC, et al. (2012) Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens 30: 1606-1613.
11. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, et al. (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54: 537-543.
12. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-3128. (Pubitemid 39492008)
13. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, et al. (2012) Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 59: 1179-1187.
14. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, et al. (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99: 323-328.
15. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, et al. (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409: 96-99.
16. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, et al. (1995) Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 147: 1016-1028.
17. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, et al. (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56: 57-65. (Pubitemid 46449664)
18. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, et al. (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103: 5060-5065.
19. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, et al. (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298. (Pubitemid 351282017)
20. Laurent C, Maria M, Pascal R, Victoria C, Ernesto MM, et al. (2012) Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arterioscler Thromb Vasc Biol.
21. Guevremont M, Martel-Pelletier J, Boileau C, Liu FT, Richard M, et al. (2004) Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3. Ann Rheum Dis 63: 636-643. (Pubitemid 38658391)
22. Spirin KS, Saghizadeh M, Lewin SL, Zardi L, Kenney MC, et al. (1999) Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res 18: 490-499. (Pubitemid 29308761)
23. Kim MS, Kim YK, Cho KH, Chung JH (2006) Regulation of type I procollagen and MMP-1 expression after single or repeated exposure to infrared radiation in human skin. Mech Ageing Dev 127: 875-882. (Pubitemid 44781346)
24. Wu VC, Kuo CC, Chang HW, Tsai CT, Lin CY, et al. (2010) Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity. Clin Chim Acta 411: 657v663.
25. Kuo CC, Wu VC, Huang KH, Wang SM, Chang CC, et al. (2011) Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group). J Renin Angiotensin Aldosterone Syst 12: 348-357.
26. Wu VC, Yang SY, Lin JW, Cheng BW, Kuo CC, et al. (2011) Kidney impairment in Primary Aldosteronism. Clin Chim Acta.
27. Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, et al. (2009) 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med 50: 1631-1637.
28. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, et al. (2002) Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 106: 1572-1585.
29. Sun Y, Ramires FJ, Weber KT (1997) Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 35: 138-147. (Pubitemid 27374751)
30. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364.
31. Ochieng J, Furtak V, Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19: 527-535. (Pubitemid 38316526)
32. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, et al. (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33: 67-75.
33. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, et al. (2010) Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55: 758-770.